Skip to main content
Premium Trial:

Request an Annual Quote

Orchid BioSciences, Thermo BioStar Deal Aims to Bring SNP-Based Diagnostics to Point-of-Care

NEW YORK, Feb. 7 - Orchid BioSciences and a unit of Thermo Electron have signed a series of technology agreements to develop and market SNP-based diagnostic tests for point-of-care applications and genotyping products for research.

Terms of the agreements call for Orchid to receive non-exclusive rights from Thermo Electron's Thermo BioStar business to develop, supply, and sell genotyping products that will combine Orchid's SNP-IT genotyping technology with BioStar's OIA biosensor technologies.

The companies also have agreed to co-develop and market SNP-based diagnostic products for point-of-care facilities.

Financial terms of the deals were not disclosed.

"Combining the two should enable us to develop and market highly innovative genotyping products for the research and diagnostics marketplaces," Donald R. Marvin, chief operating officer of Orchid BioSciences and acting general manager of Orchid Diagnostics, said in a statement.

Added Marc Casper, president of Thermo Electron's Life Sciences sector: "Through this partnership, we expect Orchid will be able to develop novel products for the growing number of researchers who want to conduct genotyping studies.

"And perhaps even more significant--together we intend to develop the diagnostic products that for the first time could make it possible for physicians to perform real-time diagnostic tests using medically relevant SNPs."

BioStar's thin-film optics technology, which uses optically coated surfaces and light, is used in a variety of applications, including detecting nucleic acids, proteins, PCR products, and pathogens, the company said.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.